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therapy in the context of molecular subgroups. Discussion 
at the meeting generated a series of consensus statements 
and recommendations from the attendees, which comment 
on the prognostic evaluation and treatment decisions of 
patients with intracranial ependymoma (WHO Grade II/III) 
based on the knowledge of its molecular subgroups. The 
major consensus among attendees was reached that treat-
ment decisions for ependymoma (outside of clinical trials) 
should not be based on grading (II vs III). Supratentorial 
and posterior fossa ependymomas are distinct diseases, 
Abstract Multiple independent genomic profiling efforts 
have recently identified clinically and molecularly distinct 
subgroups of ependymoma arising from all three anatomic 
compartments of the central nervous system (supratento-
rial brain, posterior fossa, and spinal cord). These advances 
motivated a consensus meeting to discuss: (1) the utility 
of current histologic grading criteria, (2) the integration 
of molecular-based stratification schemes in future clini-
cal trials for patients with ependymoma and (3) current 
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although the impact on therapy is still evolving. Molecular 
subgrouping should be part of all clinical trials henceforth.
Keywords Ependymoma · Subgroups · RELA · YAP1 · 
Treatment · Trial · Posterior fossa
Introduction
Ependymoma is a histologically defined intrinsic tumor that 
involves the three major anatomic compartments (supraten-
torial brain, posterior fossa, and spinal cord) of the central 
nervous system and affects both children and adults. The 
current standard of care therapy for patients with intrac-
ranial ependymoma remains surgical resection combined 
with radiotherapy. The survival benefit of chemotherapy 
for ependymoma and the prognostic ability of histopatho-
logical grading criteria to risk-stratify patients are still both 
inconclusive and contentious. No molecular or tumor-spe-
cific immunohistochemical markers are in routine current 
clinical use for ependymoma. Recent advances in the bio-
logical characterization of ependymal tumors have demon-
strated the existence of nine clinically, demographically, and 
molecularly distinct entities, with three occurring in each 
anatomic compartment. These findings offer new opportuni-
ties to create a precise, reliable, and objective platform for 
stratification of ependymoma patients, and the potential for 
altering therapeutic decisions based on molecular features. 
Herein, we discuss the current consensus on the molecular 
subgroups of intracranial ependymoma (WHO Grade II/
III) in children and adults, as well as recommendations for 
integration into future clinical trial designs. These discus-
sions and recommendations were made by a collection of 
neuro-oncologists, neurosurgeons, neuro-pathologists, radi-
ation oncologists, and basic scientists, meeting at the global 
ependymoma consensus conference (Huntsville, Ontario, 
Canada in September 2015) (Fig. 1).
The utility of histologic grading of ependymoma 
in a molecular era
Ependymomas from throughout the central nervous system 
are currently sub-divided by three histology-based grades 
used to predict the natural course of the disease and patient 
outcome [19]. However, the utility of histological grading 
of ependymoma for risk stratification has been controver-
sial and without consistent associations of tumor grade with 
patient outcome. The World Health Organization (WHO) 
Grade I tumors include myxopapillary ependymoma, which 
typically occurs in the spine, as well as subependymoma, 
which is usually intracranial. Grade I ependymomas are 
relatively easier to distinguish, occur predominantly in 
adults, and are associated with favorable clinical outcomes 
[19]. Conventional ependymomas are divided between 
WHO Grade II and WHO Grade III (anaplastic) tumors, the 
latter showing elevated mitotic activity, microvascular pro-
liferation, and tumor necrosis. Analysis of multiple cohorts 
of intracranial ependymoma highlights a wide variance in 
the utility of the Grade II versus Grade III distinction as 
a robust prognostic marker [9]. Furthermore, the utility of 
conventional histologic grading may be confounded by 
the anatomic compartment [29, 37]. These considerations 
have raised significant questions as to whether the grading 
criteria should stratify patients into different therapeutic 
regimens. It was therefore agreed upon that: (1) treatment 
decisions for ependymoma should not be based on clas-
sification and grading that is solely based on histopatho-
logical characteristics (especially, the distinction of Grade 
II versus Grade III tumors) and (2) central and combined 
histologic–molecular review and classification should be 
a principal and integral component of any future clinical 
trial. Indeed, the updated 4th edition of the WHO classi-
fication of central nervous system tumors recognizes the 
supratentorial molecular variant, ST-EPN-RELA (see next 
section), as a distinct biological and clinical disease entity 
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[20]. Integrated histo-molecular analyses of ependymal 
tumors from clinically well-annotated prospective interna-
tional trial cohorts hold promise for inclusion of additional 
molecular ependymoma ‘entities’ into the upcoming 5th 
edition of the WHO classification of CNS tumors.
Molecular subgroups of ependymal tumors in the 
central nervous system
Although molecular subgroups of ependymoma arising in 
different anatomical sites exhibit histopathological similar-
ities, their molecular profiles are easily discernable, owing 
to diverse genetic, transcriptional, and epigenetic programs 
[7, 8, 18, 22, 24, 30, 36, 37]. Functional cross-species 
analyses have provided evidence that these molecular dif-
ferences may be reflective of discrete developmental and 
cellular origins [16, 30, 33]. Based on demographic, clini-
cal, and molecular data, supported in multiple independent 
cohorts [23, 29–31, 36, 37], a full consensus was reached 
that: posterior fossa and supratentorial ependymoma are 
biologically different diseases both treated by surgery and 
radiotherapy. Future molecular characterization and clinical 
trials will assess whether posterior fossa and supratentorial 
ependymoma may benefit from different forms of therapy. 
A recent international collaborative study identified nine 
molecular subgroups of ependymal tumors, three in each 
anatomical compartment of the central nervous system, 
spine (SP), posterior fossa (PF), and supratentorial region 
(ST) [29]. One of the subgroups within each compartment 
was enriched with WHO Grade I subependymomas (SE), 
named ST-SE, PF-SE, and SP-SE. These molecular sube-
pendymomas occurred in adults only. The two other molec-
ular subgroups within the spine predominantly matched the 
histopathology-based diagnoses of myxopapillary epend-
ymoma (SP-MPE) and (WHO Grade II/III) ependymoma 
(SP-EPN). The remaining two molecular types of epend-
ymoma occurred in the posterior fossa, termed PF-EPN-
A and PF-EPN-B or alternatively posterior fossa Group A 
and B, and were independently identified in retrospective 
studies [36, 37]. PF-EPN-A tumors occur predominantly in 
infants and young children. Due to their predominant lat-
eral localization, PF-EPN-A tumors are often difficult to 
completely resect and are associated with high recurrence 
rates [37]. Conversely, PF-EPN-B tumors occur largely 
in adolescents and young adults and are associated with a 
Fig. 1  General and molecular subgroup specific consensus statements on the clinical management of intracranial ependymoma
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more favorable prognosis. More than 70% of supratento-
rial ependymomas are characterized by fusions between 
C11ORF95 and the RELA gene, and were recently termed 
ST-EPN-RELA [29, 30]. While ST-EPN-RELA tumors 
may occur in both children and adults, the remaining 
molecular subgroup of supratentorial ependymoma harbors 
recurrent fusions to the oncogene YAP1 and is enriched 
in the pediatric population [29, 30]. Since preliminary 
evidence of a small retrospective cohort indicates that 
patients with YAP1 fusions have an excellent prognosis, it 
was agreed upon that the international community should 
move rapidly toward determining whether ST-EPN-YAP1 
is a subgroup with an extremely favorable clinical outcome 
and therefore might benefit from careful therapy de-esca-
lation within the setting of a clinical trial. Retrospective 
classification of clinically well-annotated supratentorial 
ependymomas, which have been treated in clinical trials, 
is expected to give more detailed information on outcome 
within this subgroup in the near future. No consensus was 
made upon morphologically diagnosed ST-ependymomas 
without RELA/YAP1 fusion. It was felt that further investi-
gation was needed for this apparently heterogeneous group 
of tumors. It was acknowledged that such issues could be 
addressed with a DNA methylation-based molecular classi-
fication for ependymal tumors that represents an unbiased, 
robust, and uniform scheme that adequately reflects the full 
biological, clinical, and histopathological heterogeneity 
across all age groups, grades, and major anatomical CNS 
compartments. The clinical feasibility of this platform is 
supported by multiple components: (1) low sample input 
and DNA requirements, (2) robust results from formalin-
fixed paraffin-embedded (FFPE) tissue, and (3) minimal 
batch effects and assay consistency between different clini-
cal-genomic facilities. In addition to DNA methylation pat-
terns, DNA copy number profiles can be derived from this 
analysis. It is important to note that chromosome 1q gain 
has been shown to be an independent prognostic factor that 
occurs in a subset of PF-EPN-A, PF-EPN-B, and ST-EPN-
RELA tumors [12, 17, 24, 29, 32, 37]. Future integrated 
molecular efforts will explore the integration of molecular 
subgroup, copy number alterations (namely chromosome 
1q gain), and their impact on patient outcome.
Molecular sub-classification is expected to significantly 
support treatment decisions and simplify risk stratification 
processes in the immediate future, and should impact clini-
cal trial design and operation in both children and adults. A 
complete consensus was reached that molecular subgroup-
ing should be a part of all clinical trials moving forward. It 
was agreed that certification of diagnostic assays for molec-
ular subgroup detection is of high importance. However, 
it was acknowledged that there were differences between 
countries regarding certifying agencies and regulations, 
and therefore most attendees felt that it was not reasonable 
and feasible to generate a consensus statement on certifi-
cation processes. To further improve molecular diagnos-
tics and identify new prognostic factors and therapeutic 
targets, optimal tissue material for ongoing and future 
biologic discovery studies is required. The great majority 
of attendees agreed that submitting fresh-frozen samples 
should be mandatory within upcoming clinical trials for 
ependymoma. Although DNA methylation profiling can be 
performed with FFPE-derived tissue, frozen samples would 
provide optimal material for use in future applications, 
such as genome sequencing. The interpretation of any 
tumor sequencing (from a limited gene panel up to whole 
genome) would dramatically benefit from a matched con-
trol to correct for aberrations inherent to the germline. As 
such, an agreement among most attendees was established 
that submission of blood samples should also be mandatory 
for enrollment in a clinical trial. It should be recognized 
that arguments were made against the mandate of fresh-
frozen tissue, owing to the logistical issues of collection, 
storage, and submission, particularly in small community 
centers. Additionally, there were ethical concerns regarding 
the mandated submission of blood. Attendees recognized 
that efforts would need to be established to create standard 
operating procedures in smaller centers to enable reliable 
collection and submission of frozen tissue. Many of those 
agreeing on a mandate of frozen tissue and blood argued 
that given the rapid developments in the field of molecular 
genetics, with the emergence of increasingly powerful ana-
lytical devices and computational tools, the time is now to 
collect tissue specimens in combination with high-quality 
clinical data. This would enable the use of such advances to 
improve the care of future ependymoma patients.
Clinical management of intracranial ependymoma 
in the context of molecular subgroups
Clinical management of intracranial ependymomas (WHO 
Grade II/III) is challenging and the optimal treatment strat-
egy is contentious. Intracranial ependymoma, particularly 
before administration of any therapy, demonstrates pre-
dominantly locally invasive growth patterns and has only 
very low metastatic potential. Surgery plays a primary 
role for local tumor control and the extent of neurosurgi-
cal resection has been the most consistent independent 
prognostic factor reported in the last decades [5, 6, 34]. 
The favorable outcome of patients without residual disease 
and the large difference in event-free and overall survival 
between patients with complete versus incomplete resec-
tion (up to 50% in some series) have led to the concepts of 
aggressive de-bulking and second-look surgery. Such neu-
rosurgical procedures may be performed immediately fol-
lowing incomplete initial resection or after a short course 
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of chemotherapy and is currently being systematically 
evaluated in clinical trials. A comprehensive radiological 
assessment of the residual disease status is expected to give 
the highest degree of information to base potential second-
ary neurosurgical intervention decisions. Attendees agreed 
that central radiological review of pre- and post-surgical 
imaging should be a principal component of every clinical 
trial enrolling patients with ependymoma henceforth.
In addition to surgery, post-operative field radiotherapy 
dosed at 54–59.4 Gy is considered the standard of care for 
patients with non-disseminated ependymoma to lower the 
risk of local recurrence [25]. Radiation margins around the 
target volume have also decreased from 2.0 to 1.0 cm, with 
no evidence of increased frequency of tumor relapse [25]. 
Owing to the challenging localization of ependymoma, 
particularly in the case of laterally located infant posterior 
fossa tumors, proton therapy has been explored as a radia-
tion modality to spare proximal neurological structures 
[21]. In the case of recurrent ependymoma, a retrospective 
analysis demonstrated that the efficacy of re-irradiation, 
however, was associated with a decline in patient intellec-
tual function [4].
It should be emphasized that all prior studies that evalu-
ated the therapeutic value of neurosurgical interventions 
and external beam radiation in posterior fossa ependymoma 
have not accounted for molecular subgroup affiliation and 
might therefore be confounded by clinical differences in 
response to therapy between these subgroups. Data from a 
current retrospective study on four independent non-over-
lapping cohorts of posterior fossa ependymomas (n = 820 
cases) found that patients with either PF-EPN-A or PF-
EPN-B tumors benefit from gross total resection, with the 
survival rates being particularly poor for sub-totally resected 
PF-EPN-A, even in the setting of radiation therapy [31]. 
Participants at the conference concluded that for PF-EPN-
A tumors in patients older than 12 months of age who are 
treated outside of clinical trials, maximal safe surgical 
resection and focal radiotherapy should be defined as the 
standard of care. Owing to the challenging localization of 
PF-EPN-A tumors, attendees acknowledged that patients 
would benefit from being treated in specialized centers by 
experienced neurosurgeons. Since the study strongly dem-
onstrates that a large subset of patients with PF-EPN-B 
tumors who received a gross total resection did not recur, 
even in the absence of radiotherapy, it was agreed that a ran-
domized clinical trial for newly diagnosed and gross totally 
resected PF-EPN-B ependymoma comparing observation 
versus standard upfront radiation should be considered. 
Such a trial would test the possibility of therapy to be de-
escalated in some patients with PF-EPN-B ependymoma.
Observation for gross totally resected supratentorial 
ependymomas has also been advocated based on retrospec-
tive series that were not molecularly characterized. For 
example, a retrospective, multicenter study comprising 92 
patients (median age was 17.5 years, range 1–83 years) 
with gross totally resected and non-anaplastic supratento-
rial ependymal tumors did not find evidence of decreased 
progression-free or overall survival with the omission of 
external beam radiation [11]. The 5–10 year Kaplan–Meier 
estimated overall survival for the overall cohort was 83.2 
and 84.1%, respectively. Another retrospective review 
of only ten patients (median age 5.6 years, range 1.8–
15.6 years), which also included ependymomas diagnosed 
as WHO grade III, found that in some children with com-
pletely resected supratentorial ependymoma, surgery alone 
may be an acceptable treatment option [35]. The outcomes 
in the aforementioned series differed from the largest cohort 
published to date comprising 122 supratentorial ependymal 
tumors that were classified according to their DNA methyl-
ation profiles as ST-EPN-RELA, ST-EPN-YAP1 and ST-SE 
[29]. Tumors harboring C11ORF95 gene fusions to RELA 
accounted for more than 70% of supratentorial ependymo-
mas (median age 8 years, range 0–69 years) and were asso-
ciated with a poor prognosis with 5-year progression-free 
and overall survival of 29 and 75%, respectively. Inter-
estingly, the level of resection did not significantly affect 
the outcome within the ST-EPN-RELA-positive subgroup 
in this retrospective analysis in patient samples collected 
over a long period of time (>20 years). The two remain-
ing supratentorial subgroups, ST-SE and ST-EPN-YAP1, 
were restricted only to adults (median age 40 years, range 
22–76 years) and predominantly to children (median age 
1.4 years, range 0–51 years), respectively, with both of 
these variants showing an excellent prognosis. As the cited 
studies and other available collections of single cases mark-
edly differ regarding age distribution, therapy modalities 
and availability of molecular data, variations in outcome 
cannot be reliably linked to specific treatment approaches 
or molecular subgroups. It was, therefore, concluded that 
there was not enough evidence yet to recommend distinct 
treatment approaches for ST-EPN-RELA ependymoma. 
Molecular analyses of supratentorial ependymomas from 
clinically well-annotated international trial cohorts as well 
as from large retrospective cohorts with long-term follow-
up have now been initiated. The authors expect that this 
approach will help to clarify questions about the clinical 
outcome of the molecular variants of supratentorial epend-
ymoma and result in explicit therapy recommendations.
In contrast to surgery and radiotherapy, the role of 
chemotherapy in the management of ependymoma remains 
unproven despite extensive investigation. Cohorts of pedi-
atric or adult patients in which the role of chemotherapy 
was retrospectively analyzed either failed to demon-
strate a survival advantage or showed substantial variation 
between individual patients [3, 13, 28]. Two international 
randomized trials in children are currently comparing 
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post-irradiation chemotherapy to observation only, SIOP 
Ependymoma II (Europe) and ACNS0831 (USA). In an 
attempt to delay radiotherapy in very young children, driven 
by concerns about long-term treatment toxicity, several 
groups used post-operative chemotherapy approaches in 
children under 3 years with 42% being the highest rate of 
5-year progression-free survival reached to date [14, 15, 
40]. In marked contrast, extension of immediate post-oper-
ative high-dose conformal radiotherapy to children under 
the age of 3 years led to 7-year progression-free survival 
rates of 77%, albeit long-term follow-up for toxic effects on 
development are still pending [25]. For this reason, radio-
therapy deferral strategies that use chemotherapy have been 
abandoned in most institutions for children >12 months of 
age. Initial responses to chemotherapy after subtotal resec-
tion have been demonstrated [10] and the ependymoma trial 
ACNS0831 is currently assessing the role of neoadjuvant 
chemotherapy and second-look surgery, with a combined 
chemotherapy regimen of vincristine, cisplatin, etoposide, 
and cyclophosphamide. To date, there is no chemotherapeu-
tic regimen that can routinely be recommended outside the 
context of a clinical trial. Since the consensus for therapeu-
tic management in the molecularly well-defined PF-EPN-A 
subgroup does not include any systemic therapy, it will defi-
nitely open new avenues for rather rapid implementation of 
innovative trials for this devastating disease.
Model development and novel therapeutics
Because of the recognition that ependymal tumors com-
prise molecularly distinct subtypes, with potentially distinct 
clinical management, the generation of subgroup-specific 
pre-clinical models for the development and assessment of 
novel therapies is required. The identification of candidate 
cells of origin for ependymoma has permitted the genera-
tion of novel mouse models that can be leveraged for novel 
therapeutic discovery and evaluation [1, 16, 27, 30]. Ephrin 
receptor B2 (EPHB2)-driven ST ependymoma models—
also highly expressed in ST-EPN-RELA tumors—have 
pinpointed 5-fluorouracil treatment as a potential cytotoxic 
therapy with efficacy in murine models and is currently 
being evaluated in early phase ependymoma clinical trials 
[1, 16, 38]. Owing to the clear genetic drivers of ST-EPN-
RELA and ST-EPN-YAP1, transcriptionally faithful mouse 
models are currently generated, which will create similar 
opportunities to identify druggable targets against these 
specific subtypes of ependymoma [30]. In parallel, patient-
derived xenograft (PDX) models have been established, 
permitting further therapeutic evaluation of novel drugs and 
compounds against ependymoma [2, 26, 39]. In the case of 
PF-EPN-A, the absence of a clear genetic driver has ham-
pered efforts to create genetic mouse models of the disease. 
Moving forward, it will be important that pre-clinical mod-
els are developed in the context of ependymoma subgroups, 
such that molecular stratification of these tumors is paired 
with specific therapeutic targets.
Conclusions
We now recognize that ependymal tumors from different 
compartments of the central nervous system are biologi-
cally distinct and there are phenotypically divergent sub-
groups within each anatomic compartment. Future clinical 
trials, the development of pre-clinical model systems, and 
the identification and testing of subtype-specific therapeu-
tics must accompany molecular classification to be useful 
to ependymoma patients and to the neuro-oncology com-
munity. The differentiation between histologically defined 
grade II versus grade III/anaplastic ependymomas is prob-
lematic and of limited utility for clinical decision-making, 
and therefore should be used with great caution outside 
the setting of a clinical trial. For patients with PF-EPN-A 
ependymoma over the age of 12 months of age, the recom-
mended standard of care is maximal safe micro-neurosur-
gical removal followed by local radiotherapy, but probably 
does not include the routine use of chemotherapy outside 
the setting of a clinical trial. A subset of PF-EPN-B epend-
ymoma patients who undergo gross total micro-neurosur-
gical resection are likely cured in the absence of radio-
therapy, and a clinical trial to test the possibility to avoid 
radiotherapy in the context of complete resection for PF-
EPN-B patients is indicated. The characteristics and het-
erogeneity between molecular subgroups of supratentorial 
ependymoma require additional study before specific treat-
ment recommendations can be made. The division of an 
already uncommon entity (“ependymoma”) into nine new 
entities will necessitate great co-operation and international 
collaboration with the pediatric and adult neuro-oncology 
community if clinical trials are to be properly and expedi-
tiously completed.
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